DAY 2 - Saturday, February 4, 2012
NEW HORIZONS FORUM
Diverse developments shape future of glaucoma care
San Francisco—The future of glaucoma management is happening now and is being shaped by developments in health reform, financing reform, information technology, ongoing research in drug delivery systems, and the emerging potential for personalized targeted therapy, said George A. Cioffi, MD. » MORE
Safer surgery, better diagnostics are focus
San Francisco—Developments in the area of glaucoma devices include new technology for surgical solutions and advances in imaging platforms. Speakers provided an update on ongoing research during a session moderated by Alan Crandall, MD. » MORE
Improvements in drug delivery, IOP monitoring key
San Francisco—Development of sophisticated drug delivery systems able to overcome the problem of medication nonadherence and of technology for remote, long-term monitoring of IOP is cutting edge for advancing glaucoma care. Representatives from industry described their companies’ novel approaches in these areas during a session moderated by Eliot Lazar, MD, ELCON Medical. » MORE
ROCK inhibitors aim of glaucoma drug development
San Francisco—Several companies developing new pharmaceutical treatments for glaucoma are aiming to be the first to bring a brand new drug class into the therapeutic armamentarium since the first prostaglandin analogue was introduced 15 years ago. Industry representatives reported on their pipelines in a session co-moderated by Anthony P. Adamis, MD, Genentech, and Paul Chaney, PanOptica. » MORE
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
|
